CIBA Vision raised its total sales by 19 percent to 1,181 million Swiss francs (e787m-$652m) in the first 9 months of this year, but only by 9 percent in local currencies. The main growth factor was the launch of Visudyne, a breakthrough treatment for age-related macular degeneration, whose sales have ...
Buying a membership today will give you:
To continue reading this article register now.